WO/2017/173478 | ACOUSTIC WAVE MEDIATED NON-INVASIVE DRUG DELIVERY |
JP4630395 | Solution for diagnosis or treatment of tissue lesions |
JP5977009 | Active foaming object |
TIAN JIDE (US)
WO2021195297A1 | 2021-09-30 |
US20190161529A1 | 2019-05-30 | |||
US20200054595A1 | 2020-02-20 |
MUSHTAQ HINA, QURESHI MARIA, KARACHI LNH, AHSAN IRFAN: "Pakistan Journal of Neurological Sciences (PJNS) Acute disseminated encephalomyelitis in a middle age female", PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES (PJNS), 31 March 2018 (2018-03-31), pages 29 - 31, XP055931680, Retrieved from the Internet
What is claimed is: 1. A method for ameliorating an infection-related medical condition, comprising administering to a patient in need thereof an effective amount of a GABA- receptor agonist. 2. The method of Claim 1, wherein said infection is a bacterial infection. 3. The method of Claim 1, wherein said infection is a fungal infection. 4. The method of Claim 1, wherein said infection is a viral infection. 5. The method of any one of Claims 1-4, wherein said GABA-receptor agonist is selected from the group consisting of: GABAA-receptor agonists, GABAB- receptor agonists, and GABAA-rho receptor agonists. 6. The method of Claim 5, wherein said GABAA-receptor agonist is selected from the group consisting of: α5IA, adipiplon, beta-alanine, bretazenil, CL-218,872, (-)-epigallocatechin-3-gallate, GABA, gaboxadol, homotaurine, imidazenil, isoguvacine, L-838,417, muscimol, piperidine-4-sulfonic acid, progabide, QH- ii-066, SL-651,498, taurine, zolpidem, and 3-acyl-4-quinolones. 7. The method of Claim 5, wherein GABAB-receptor agonist is selected from the group consisting of: baclofen, CGP-44532, GABA, gamma-hydroxybutyrate, isovaline, lesogaberan, phenibut, 3-aminopropylphosphinic acid, and 3- aminopropyl(methyl)phosphinic acid (SKF-97541). 8. The method of Claim 5, wherein said GABAA-rho receptor agonist is selected from the group consisting of: CACA, CAMP, and GABOB. 9. The method of any one of Claims 1-8, wherein an effective amount of a positive allosteric modulator (PAM) is also administered. 10. The method of Claim 9, wherein said PAM is administered concurrently or in a staggered format. 11. The method of Claim 9 or Claim 10, wherein said PAM is selected from the group consisting of: alcohol (ethanol), barbiturates, benzodiazepines, BHFF, BHF-177, BSPP, certain carbamates, CGP-7930, cinacalcet, etomidate, fendiline, glutethimide, GS-39783, kavalactones, lanthanum, meprobamate, neuroactive steroids, neurosteroids, niacin/niacinamide, nonbenzodiazepines, propofol, quinazolinones, riluzole, stiripentol, theanine, thienodiazepines, valerenic acid, and volatile/inhaled anesthetics. 12. The method of any one of Claims 1-11, wherein said GABA-receptor agonist is GABA. 13. The method of any one of Claims 1-11, wherein said GABA-receptor agonist is homotaurine. 14. The method of any one of Claims 1 and 4-13, wherein said infection is related to or results from any strain of: human coronavirus, human coronavirus OC43 (“HCoV-OC43”), human coronavirus HKU1 (“HCoV-HKU1”), human coronavirus 229E (“HCoV-229E”), human coronavirus NL63 (“HCoV-NL63”), Middle East respiratory syndrome-related coronavirus (“MERS-CoV”), severe acute respiratory syndrome coronavirus (“SARS-CoV”), and/or SARS-CoV-2. 15. The method of any one of Claims 1-14, wherein said infection results in one or more of: death, edema, excess immune response, fever, illness, increased secretion of inflammatory factors, increased viral replication, inflammation, lethargy, pneumonia, pneumonitis, and tussis. 16. The method of any one of Claims 1-15, wherein said administration occurs intradermally, intramuscularly, intraperitoneally, intravenously, orally, subcutaneously, sublingually, via aerosol delivery, or via a combination of delivery routes. 17. The method of Claim 16, wherein said administration occurs orally, sublingually, and/or via aerosol delivery. 18. The method of any one of Claims 1-17, wherein an effective amount of an anti-inflammatory compound is also administered. 19. The method of Claim 18, wherein said anti-inflammatory compound is a corticosteroid. 20. The method of Claim 19, wherein said corticosteroid is dexamethasone. 21. The method of any one of Claims 18-20, wherein said anti-inflammatory compound is also administered concurrently or in a staggered format with said GABA-receptor agonist and/or PAM. 22. A method for ameliorating and/or preventing a coronavirus-related medical condition, comprising administering to a patient in need thereof an effective amount of a GABA-receptor agonist. 23. The method of Claim 22, wherein said GABA-receptor agonist is selected from the group consisting of: GABAA-receptor agonists, GABAB-receptor agonists, and GABAA-rho receptor agonists. 24. The method of Claim 23, wherein said GABAA-receptor agonist is selected from the group consisting of: α5IA, adipiplon, beta-alanine, bretazenil, CL- 218,872, (-)-epigallocatechin-3-gallate, GABA, gaboxadol, homotaurine, imidazenil, isoguvacine, L-838,417, muscimol, piperidine-4-sulfonic acid, progabide, QH-ii-066, SL-651,498, taurine, zolpidem, and 3-acyl-4- quinolones. 25. The method of Claim 23, wherein said GABAB-receptor agonist is selected from the group consisting of: baclofen, CGP-44532, GABA, gamma- hydroxybutyrate, isovaline, lesogaberan, phenibut, 3-aminopropylphosphinic acid, and 3-aminopropyl(methyl)phosphinic acid (SKF-97541). 26. The method of Claim 23, wherein said GABAA-rho receptor agonist is selected from the group consisting of: CACA, CAMP, and GABOB. 27. The method of any one of Claims 22-26, wherein an effective amount of a positive allosteric modulator (PAM) is also administered. 28. The method of Claim 27, wherein said PAM is administered concurrently or in a staggered format. 29. The method of Claim 27 or Claim 28, wherein said PAM is selected from the group consisting of: alcohol (ethanol), barbiturates, benzodiazepines, BHFF, BHF-177, BSPP, certain carbamates, CGP-7930, cinacalcet, etomidate, fendiline, glutethimide, GS-39783, kavalactones, lanthanum, meprobamate, neuroactive steroids, neurosteroids, niacin/niacinamide, nonbenzodiazepines, propofol, quinazolinones, riluzole, stiripentol, theanine, thienodiazepines, valerenic acid, and volatile/inhaled anesthetics. 30. The method of any one of Claims 22-29, wherein said GABA-receptor agonist is GABA. 31. The method of any one of Claims 22-29, wherein said GABA-receptor agonist is homotaurine. 32. The method of any one of Claims 22-31, wherein said coronavirus-related medical condition is COVID-19. 33. The method of any one of Claims 22-31, wherein said medical condition is related to or results from any strain of: human coronavirus, human coronavirus OC43 (“HCoV-OC43”), human coronavirus HKU1 (“HCoV- HKU1”), human coronavirus 229E (“HCoV-229E”), human coronavirus NL63 (“HCoV-NL63”), Middle East respiratory syndrome-related coronavirus (“MERS-CoV”), severe acute respiratory syndrome coronavirus (“SARS- CoV”), and/or SARS-CoV-2. 34. The method of any one of Claims 22-33, wherein said coronavirus-related medical condition is caused by infection with the SARS-CoV-2 virus. 35. The method of any one of Claims 22-34, wherein said coronavirus-related medical condition comprises one or more of: death, excess immune response, fever, illness, inflammation, lethargy, pneumonia, pneumonitis, and tussis. 36. The method of any one of Claims 22-35, wherein said administration occurs intradermally, intramuscularly, intraperitoneally, intravenously, orally, subcutaneously, sublingually, via aerosol delivery, or via a combination of delivery routes. 37. The method of Claim 36, wherein said administration occurs orally, sublingually, and/or via aerosol delivery. 38. The method of any one of Claims 22-37, wherein an effective amount of an anti-inflammatory compound is also administered. 39. The method of Claim 38, wherein said anti-inflammatory compound is a corticosteroid. 40. The method of Claim 39, wherein said corticosteroid is dexamethasone. 41. The method of any one of Claims 38-40, wherein said anti-inflammatory compound is also administered concurrently or in a staggered format with said GABA-receptor agonist and/or PAM. 42. A method for inhibiting coronavirus replication in a patient, comprising administering to a patient in need thereof an effective amount of a GABA- receptor agonist. 43. The method of Claim 42, wherein said GABA-receptor agonist is selected from the group consisting of: GABAA-receptor agonists, GABAB-receptor agonists, and GABAA-rho receptor agonists. 44. The method of Claim 43, wherein said GABAA-receptor agonist is selected from the group consisting of: α5IA, adipiplon, beta-alanine, bretazenil, CL- 218,872, (-)-epigallocatechin-3-gallate, GABA, gaboxadol, homotaurine, imidazenil, isoguvacine, L-838,417, muscimol, piperidine-4-sulfonic acid, progabide, QH-ii-066, SL-651,498, taurine, zolpidem, and 3-acyl-4- quinolones. 45. The method of Claim 43, wherein said GABAB-receptor agonist is selected from the group consisting of: baclofen, CGP-44532, GABA, gamma- hydroxybutyrate, isovaline, lesogaberan, phenibut, 3-aminopropylphosphinic acid, and 3-aminopropyl(methyl)phosphinic acid (SKF-97541). 46. The method of Claim 43, wherein said GABAA-rho receptor agonist is selected from the group consisting of: CACA, CAMP, and GABOB. 47. The method of any one of Claims 42-46, wherein an effective amount of a positive allosteric modulator (PAM) is also administered. 48. The method of Claim 47, wherein said PAM is administered concurrently or in a staggered format. 49. The method of Claim 47 or Claim 48, wherein said PAM is selected from the group consisting of: alcohol (ethanol), barbiturates, benzodiazepines, BHFF, BHF-177, BSPP, certain carbamates, CGP-7930, cinacalcet, etomidate, fendiline, glutethimide, GS-39783, kavalactones, lanthanum, meprobamate, neuroactive steroids, neurosteroids, niacin/niacinamide, nonbenzodiazepines, propofol, quinazolinones, riluzole, stiripentol, theanine, thienodiazepines, valerenic acid, and volatile/inhaled anesthetics. 50. The method of any one of Claims 42-49, wherein said GABA-receptor agonist is GABA. 51. The method of any one of Claims 42-49, wherein said GABA-receptor agonist is homotaurine. 52. The method of any one of Claims 42-51, wherein said coronavirus is any strain of: human coronavirus, human coronavirus OC43 (“HCoV-OC43”), human coronavirus HKU1 (“HCoV-HKU1”), human coronavirus 229E (“HCoV- 229E”), human coronavirus NL63 (“HCoV-NL63”), Middle East respiratory syndrome-related coronavirus (“MERS-CoV”), severe acute respiratory syndrome coronavirus (“SARS-CoV”), and/or SARS-CoV-2. 53. The method of any one of Claims 42-52, wherein said administration occurs intradermally, intramuscularly, intraperitoneally, intravenously, orally, subcutaneously, sublingually, via aerosol delivery, or via a combination of delivery routes. 54. The method of Claim 53, wherein said administration occurs orally, sublingually, and/or via aerosol delivery. 55. The method of any one of Claims 42-54, wherein an effective amount of an anti-inflammatory compound is also administered. 56. The method of Claim 55, wherein said anti-inflammatory compound is a corticosteroid. 57. The method of Claim 56, wherein said corticosteroid is dexamethasone. 58. The method of any one of Claims 55-57, wherein said anti-inflammatory compound is also administered concurrently or in a staggered format with said GABA-receptor agonist and/or PAM. 59. A method for ameliorating and/or treating coronavirus-induced medical condition, comprising administering to a patient in need thereof an effective amount of a GABA-receptor agonist. 60. The method of Claim 59, wherein said GABA-receptor agonist is selected from the group consisting of: GABAA-receptor agonists, GABAB-receptor agonists, and GABAA-rho receptor agonists. 61. The method of Claim 60, wherein said GABAA-receptor agonist is selected from the group consisting of: α5IA, adipiplon, beta-alanine, bretazenil, CL- 218,872, (-)-epigallocatechin-3-gallate, GABA, gaboxadol, homotaurine, imidazenil, isoguvacine, L-838,417, muscimol, piperidine-4-sulfonic acid, progabide, QH-ii-066, SL-651,498, taurine, zolpidem, and 3-acyl-4- quinolones. 62. The method of Claim 60, wherein said GABAB-receptor agonist is selected from the group consisting of: baclofen, CGP-44532, GABA, gamma- hydroxybutyrate, isovaline, lesogaberan, phenibut, 3-aminopropylphosphinic acid, and 3-aminopropyl(methyl)phosphinic acid (SKF-97541). 63. The method of Claim 60, wherein said GABAA-rho receptor agonist is selected from the group consisting of: CACA, CAMP, and GABOB. 64. The method of any one of Claims 59-63, wherein an effective amount of a positive allosteric modulator (PAM) is also administered. 65. The method of Claim 64, wherein said PAM is administered concurrently or in a staggered format. 66. The method of Claim 64 or Claim 65, wherein said PAM is selected from the group consisting of: alcohol (ethanol), barbiturates, benzodiazepines, BHFF, BHF-177, BSPP, certain carbamates, CGP-7930, cinacalcet, etomidate, fendiline, glutethimide, GS-39783, kavalactones, lanthanum, meprobamate, neuroactive steroids, neurosteroids, niacin/niacinamide, nonbenzodiazepines, propofol, quinazolinones, riluzole, stiripentol, theanine, thienodiazepines, valerenic acid, and volatile/inhaled anesthetics. 67. The method of any one of Claims 59-66, wherein said GABA-receptor agonist is GABA. 68. The method of any one of Claims 59-66, wherein said GABA-receptor agonist is homotaurine. 69. The method of any one of Claims 59-68, wherein said medical condition is related to or results from any strain of: human coronavirus, human coronavirus OC43 (“HCoV-OC43”), human coronavirus HKU1 (“HCoV- HKU1”), human coronavirus 229E (“HCoV-229E”), human coronavirus NL63 (“HCoV-NL63”), Middle East respiratory syndrome-related coronavirus (“MERS-CoV”), severe acute respiratory syndrome coronavirus (“SARS- CoV”), and/or SARS-CoV-2. 70. The method of Claim 69, wherein said medical condition is related to or results from any strain of the SARS-CoV-2 virus. 71. The method of any one of Claims 59-70, wherein said medical condition results in one or more of: death, fever, illness, inflammation, lethargy, pneumonia, pneumonitis, and tussis. 72. The method of any one of Claims 59-71, wherein said administration occurs intradermally, intramuscularly, intraperitoneally, intravenously, orally, subcutaneously, sublingually, via aerosol delivery, or via a combination of delivery routes. 73. The method of Claim 72, wherein said administration occurs orally, sublingually, and/or via aerosol delivery. 74. The method of any one of Claims 59-73, wherein an effective amount of an anti-inflammatory compound is also administered. 75. The method of Claim 74, wherein said anti-inflammatory compound is a corticosteroid. 76. The method of Claim 75, wherein said corticosteroid is dexamethasone. 77. The method of any one of Claims 74-76, wherein said anti-inflammatory compound is also administered concurrently or in a staggered format with said GABA-receptor agonist and/or PAM. 78. A method for inhibit viral replication in a patient, comprising administering to a patient in need thereof an effective amount of a GABA-receptor agonist. 79. The method of any one of Claim 78, wherein said GABA-receptor agonist is selected from the group consisting of: GABAA-receptor agonists, GABAB- receptor agonists, and GABAA-rho receptor agonists. 80. The method of Claim 79, wherein said GABAA-receptor agonist is selected from the group consisting of: α5IA, adipiplon, beta-alanine, bretazenil, CL- 218,872, (-)-epigallocatechin-3-gallate, GABA, gaboxadol, homotaurine, imidazenil, isoguvacine, L-838,417, muscimol, piperidine-4-sulfonic acid, progabide, QH-ii-066, SL-651,498, taurine, zolpidem, and 3-acyl-4- quinolones. 81. The method of Claim 79, wherein GABAB-receptor agonist is selected from the group consisting of: baclofen, CGP-44532, GABA, gamma- hydroxybutyrate, isovaline, lesogaberan, phenibut, 3-aminopropylphosphinic acid, and 3-aminopropyl(methyl)phosphinic acid (SKF-97541). 82. The method of Claim 79, wherein said GABAA-rho receptor agonist is selected from the group consisting of: CACA, CAMP, and GABOB. 83. The method of any one of Claims 78-82, wherein an effective amount of a positive allosteric modulator (PAM) is also administered. 84. The method of Claim 84, wherein said PAM is administered concurrently or in a staggered format. 85. The method of Claim 83 or Claim 84, wherein said PAM is selected from the group consisting of: alcohol (ethanol), barbiturates, benzodiazepines, BHFF, BHF-177, BSPP, certain carbamates, CGP-7930, cinacalcet, etomidate, fendiline, glutethimide, GS-39783, kavalactones, lanthanum, meprobamate, neuroactive steroids, neurosteroids, niacin/niacinamide, nonbenzodiazepines, propofol, quinazolinones, riluzole, stiripentol, theanine, thienodiazepines, valerenic acid, and volatile/inhaled anesthetics. 86. The method of any one of Claims 78-85, wherein said GABA-receptor agonist is GABA. 87. The method of any one of Claims 78-85, wherein said GABA-receptor agonist is homotaurine. 88. The method of any one of Claims 78-85, wherein said virus whose replication is being reduced is any strain of: human coronavirus, human coronavirus OC43 (“HCoV-OC43”), human coronavirus HKU1 (“HCoV-HKU1”), human coronavirus 229E (“HCoV-229E”), human coronavirus NL63 (“HCoV-NL63”), Middle East respiratory syndrome-related coronavirus (“MERS-CoV”), severe acute respiratory syndrome coronavirus (“SARS-CoV”), and/or SARS-CoV-2. 89. The method of any one of Claims 78-88, wherein said viral replication results in one or more of: death, edema, excess immune response, fever, illness, increased secretion of inflammatory factors, increased viral replication, inflammation, lethargy, pneumonia, pneumonitis, and tussis. 90. The method of any one of Claims 78-89, wherein said administration occurs intradermally, intramuscularly, intraperitoneally, intravenously, orally, subcutaneously, sublingually, via aerosol delivery, or via a combination of delivery routes. 91. The method of Claim 90, wherein said administration occurs orally, sublingually, and/or via aerosol delivery. 92. The method of any one of Claims 78-91, wherein an effective amount of an anti-inflammatory compound is also administered. 93. The method of Claim 92, wherein said anti-inflammatory compound is a corticosteroid. 94. The method of Claim 93, wherein said corticosteroid is dexamethasone. 95. The method of any one of Claims 92-94, wherein said anti-inflammatory compound is also administered concurrently or in a staggered format with said GABA-receptor agonist and/or PAM. 96. A method for ameliorating and/or preventing a respiratory virus-related medical condition, comprising administering to a patient in need thereof an effective amount of a GABA-receptor agonist. 97. The method of Claim 96, wherein said GABA-receptor agonist is selected from the group consisting of: GABAA-receptor agonists, GABAB-receptor agonists, and GABAA-rho receptor agonists. 98. The method of Claim 97, wherein said GABAA-receptor agonist is selected from the group consisting of: α5IA, adipiplon, beta-alanine, bretazenil, CL- 218,872, (-)-epigallocatechin-3-gallate, GABA, gaboxadol, homotaurine, imidazenil, isoguvacine, L-838,417, muscimol, piperidine-4-sulfonic acid, progabide, QH-ii-066, SL-651,498, taurine, zolpidem, and 3-acyl-4- quinolones. 99. The method of Claim 97, wherein said GABAB-receptor agonist is selected from the group consisting of: baclofen, CGP-44532, GABA, gamma- hydroxybutyrate, isovaline, lesogaberan, phenibut, 3-aminopropylphosphinic acid, and 3-aminopropyl(methyl)phosphinic acid (SKF-97541). 100. The method of Claim 97, wherein said GABAA-rho receptor agonist is selected from the group consisting of: CACA, CAMP, and GABOB. 101. The method of any one of Claims 96-100, wherein an effective amount of a positive allosteric modulator (PAM) is also administered. 102. The method of Claim 101, wherein said PAM is administered concurrently or in a staggered format. 103. The method of Claim 101 or Claim 102, wherein said PAM is selected from the group consisting of: alcohol (ethanol), barbiturates, benzodiazepines, BHFF, BHF-177, BSPP, certain carbamates, CGP-7930, cinacalcet, etomidate, fendiline, glutethimide, GS-39783, kavalactones, lanthanum, meprobamate, neuroactive steroids, neurosteroids, niacin/niacinamide, nonbenzodiazepines, propofol, quinazolinones, riluzole, stiripentol, theanine, thienodiazepines, valerenic acid, and volatile/inhaled anesthetics. 104. The method of any one of Claims 96-103, wherein said GABA-receptor agonist is GABA. 105. The method of any one of Claims 96-103, wherein said GABA-receptor agonist is homotaurine. 106. The method of any one of Claims 96-105, wherein said respiratory virus- related medical condition is COVID-19. 107. The method of any one of Claims 96-106, wherein said respiratory virus- related medical condition is related to or results from any strain of: human coronavirus, human coronavirus OC43 (“HCoV-OC43”), human coronavirus HKU1 (“HCoV-HKU1”), human coronavirus 229E (“HCoV-229E”), human coronavirus NL63 (“HCoV-NL63”), Middle East respiratory syndrome-related coronavirus (“MERS-CoV”), severe acute respiratory syndrome coronavirus (“SARS-CoV”), and/or SARS-CoV-2. 108. The method of any one of Claims 96-107, wherein said respiratory virus- related medical condition is caused by infection with the SARS-CoV-2 virus. 109. The method of any one of Claims 96-108, wherein said respiratory virus- related medical condition comprises one or more of: death, excess immune response, fever, illness, inflammation, lethargy, pneumonia, pneumonitis, and tussis. 110. The method of any one of Claims 96-109, wherein said administration occurs intradermally, intramuscularly, intraperitoneally, intravenously, orally, subcutaneously, sublingually, via aerosol delivery, or via a combination of delivery routes. 111. The method of Claim 110, wherein said administration occurs orally, sublingually, and/or via aerosol delivery. 112. The method of any one of Claims 96-111, wherein an effective amount of an anti-inflammatory compound is also administered. 113. The method of Claim 112, wherein said anti-inflammatory compound is a corticosteroid. 114. The method of Claim 113, wherein said corticosteroid is dexamethasone. 115. The method of any one of Claims 112-114, wherein said anti-inflammatory compound is also administered concurrently or in a staggered format with said GABA-receptor agonist and/or PAM. 116. A method for ameliorating and/or modulating dysregulated immune response in a patient suffering from an infection, comprising administering to said patient an effective amount of a GABA-receptor agonist. 117. The method of Claim 116, wherein said infection is a bacterial infection. 118. The method of Claim 116, wherein said infection is a fungal infection. 119. The method of Claim 116, wherein said infection is a viral infection. 120. The method of any one of Claims 116-119, wherein said GABA-receptor agonist is selected from the group consisting of: GABAA-receptor agonists, GABAB-receptor agonists, and GABAA-rho receptor agonists. 121. The method of Claim 120, wherein said GABAA-receptor agonist is selected from the group consisting of: α5IA, adipiplon, beta-alanine, bretazenil, CL- 218,872, (-)-epigallocatechin-3-gallate, GABA, gaboxadol, homotaurine, imidazenil, isoguvacine, L-838,417, muscimol, piperidine-4-sulfonic acid, progabide, QH-ii-066, SL-651,498, taurine, zolpidem, and 3-acyl-4- quinolones. 122. The method of Claim 120, wherein GABAB-receptor agonist is selected from the group consisting of: baclofen, CGP-44532, GABA, gamma- hydroxybutyrate, isovaline, lesogaberan, phenibut, 3-aminopropylphosphinic acid, and 3-aminopropyl(methyl)phosphinic acid (SKF-97541). 123. The method of Claim 120, wherein said GABAA-rho receptor agonist is selected from the group consisting of: CACA, CAMP, and GABOB. 124. The method of any one of Claims 116-123, wherein an effective amount of a positive allosteric modulator (PAM) is also administered. 125. The method of Claim 124, wherein said PAM is administered concurrently or in a staggered format. 126. The method of Claim 124 or Claim 125, wherein said PAM is selected from the group consisting of: alcohol (ethanol), barbiturates, benzodiazepines, BHFF, BHF-177, BSPP, certain carbamates, CGP-7930, cinacalcet, etomidate, fendiline, glutethimide, GS-39783, kavalactones, lanthanum, meprobamate, neuroactive steroids, neurosteroids, niacin/niacinamide, nonbenzodiazepines, propofol, quinazolinones, riluzole, stiripentol, theanine, thienodiazepines, valerenic acid, and volatile/inhaled anesthetics. 127. The method of any one of Claims 116-126, wherein said GABA-receptor agonist is GABA. 128. The method of any one of Claims 116-126, wherein said GABA-receptor agonist is homotaurine. 129. The method of any one of Claims 116-128, wherein said infection is related to or results from any strain of: human coronavirus, human coronavirus OC43 (“HCoV-OC43”), human coronavirus HKU1 (“HCoV-HKU1”), human coronavirus 229E (“HCoV-229E”), human coronavirus NL63 (“HCoV-NL63”), Middle East respiratory syndrome-related coronavirus (“MERS-CoV”), severe acute respiratory syndrome coronavirus (“SARS-CoV”), and/or SARS-CoV-2. 130. The method of any one of Claims 116-129, wherein said infection results in one or more of: death, edema, excess immune response, fever, illness, increased secretion of inflammatory factors, increased viral replication, inflammation, lethargy, pneumonia, pneumonitis, and tussis. 131. The method of any one of Claims 116-130, wherein said dysregulated immune response manifests as one or more of: increased alveolar fluid, inflammation of the lungs, and impaired lung function. 132. The method of any one of Claims 116-131, wherein said administration occurs intradermally, intramuscularly, intraperitoneally, intravenously, orally, subcutaneously, sublingually, via aerosol delivery, or via a combination of delivery routes. 133. The method of Claim 132, wherein said administration occurs orally, sublingually, and/or via aerosol delivery. 134. The method of any one of Claims 116-133, wherein an effective amount of an anti-inflammatory compound is also administered. 135. The method of Claim 134, wherein said anti-inflammatory compound is a corticosteroid. 136. The method of Claim 135, wherein said corticosteroid is dexamethasone. 137. The method of any one of Claims 134-136, wherein said anti-inflammatory compound is also administered concurrently or in a staggered format with said GABA-receptor agonist and/or PAM. |
are reduced, it will represent a new pathway to limit coronavirus replication in the lungs. Example 6 – GABA-Receptor Agonist Treatment at the First Signs of Illness Improves Outcome An effective amount of one or more GABA-receptor agonists, either alone or in combination with: one or more PAMs, anti-inflammatory compounds, and/or antiviral treatments, e.g., one that limits viral replication or impacts other viral functions, administered concurrently or in a staggered format to a patient in need thereof at the first signs of illness, improves outcome for the patient. Example 7 – GABA-Receptor Agonist Treatment After Serious Illness Develops Improves Outcome An effective amount of one or more GABA-receptor agonists, either alone or in combination with: one or more PAMs, anti-inflammatory compounds, and/or antiviral treatments, e.g., one that limits viral replication or impacts other viral functions, administered concurrently or in a staggered format to a patient in need thereof after serious illness develops, improves outcome for the patient. Example 8 – GABA-Receptor Agonist Treatment Optimized for the Stage of Disease Process Improves Outcome An effective amount of one or more GABA-receptor agonists, either alone or in combination with: one or more PAMs, anti-inflammatory compounds, and/or antiviral treatments, e.g., one that limits viral replication or impacts other viral functions, administered concurrently or in a staggered format to a patient in need thereof at a time optimized for the stage of disease process, improves outcome for the patient. Example 9 – GABA-Receptor Agonist Treatment Optimized for the Stage of Disease Process Improves Outcome An effective amount of one or more GABA-receptor agonists, either alone or in combination with: one or more PAMs, anti-inflammatory compounds, and/or antiviral treatments, e.g., one that limits viral replication or impacts other viral functions, administered concurrently or in a staggered format to a patient in need thereof at a time optimized for the stage of disease process, improves outcome for the patient. Example 10 – GABA-Receptor Agonist Treatment Administered as Precision Medication Based Upon the Patient’s Genotype and/or Biomarkers Improves Outcome An effective amount of one or more GABA-receptor agonists, either alone or in combination with: one or more PAMs, anti-inflammatory compounds, and/or antiviral treatments, e.g., one that limits viral replication or impacts other viral functions, administered concurrently or in a staggered format to a patient in need thereof as precision medication based upon the patient’s genotype and/or biomarkers, improves outcome for the patient.
REFERENCES 1. Tian J, Yong J, Dang H, Kaufman DL. Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity. 2011;44:465-70. PubMed PMID: 21604972. 2. Bhat R, Axtell R, Mitra A, Miranda M, Lock C, Tsien RW, Steinman L. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci U S A. 2010;107(6):2580-5. PubMed PMID: 20133656; PMCID: PMC2823917. 3. Rane MJ, Gozal D, Butt W, Gozal E, Pierce WM, Jr., Guo SZ, Wu R, Goldbart AD, Thongboonkerd V, McLeish KR, Klein JB. Gamma-amino butyric acid type B receptors stimulate neutrophil chemotaxis during ischemia-reperfusion. J Immunol. 2005;174(11):7242-9. PubMed PMID: 15905570. 4. Lee M, Schwab C, McGeer PL. Astrocytes are GABAergic cells that modulate microglial activity. Glia. 2011;59(1):152-65. doi: 10.1002/glia.21087. PubMed PMID: 21046567. 5. Januzi L, Poirier JW, Maksoud MJE, Xiang YY, Veldhuizen RAW, Gill SE, Cregan SP, Zhang H, Dekaban GA, Lu WY. Autocrine GABA signaling distinctively regulates phenotypic activation of mouse pulmonary macrophages. Cell Immunol. 2018;332:7-23. Epub 2018/07/19. doi: 10.1016/j.cellimm.2018.07.001. PubMed PMID: 30017085. 6. Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J Immunol. 2004;173(8):5298-304. PubMed PMID: 15470076. 7. Tian J, Dang H, Nguyen AV, Chen Z, Kaufman DL. Combined therapy with GABA and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating T-cell autoimmunity and promoting beta-cell replication in newly diabetic NOD mice. Diabetes. 2014;63(9):3128-34. doi: 10.2337/db13-1385. PubMed PMID: 25146474; PMCID: PMC4141368. 8. Tian J, Dang H, O’Laco K, Song M, Tiu B-C, S G, Zakarian C, Kaufman D. Homotaurine treatment enhances CD4+ and CD8+ Treg responses and synergizes with low-dose anti-CD3 to enhance diabetes remission in type 1 diabetic mice. ImmuoHorizons.2019:Oct 21;3(10):498-510. doi: 10.4049/immunohorizons.1900019; PMCID: PMC6823932 9. Tian J, Dang H, Wallner M, Olsen R, Kaufman DL. Homotaurine, a safe blood- brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. Sci Rep. 2018;8(1):16555. Epub 2018/11/10. doi: 10.1038/s41598-018-32733-3. PubMed PMID: 30410049; PMCID: PMC6224391. 10. Tian J, Dang HN, Yong J, Chui WS, Dizon MP, Yaw CK, Kaufman DL. Oral treatment with gamma-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. PLoS One. 2011;6(9):e25338. doi: 10.1371/journal.pone.0025338. PubMed PMID: 21966503; PMCID: PMC3178643. 11. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M, Salome B, Esai Selvan M, Spindler MP, Tan J, van der Heide V, Gregory JK, Alexandropoulos K, Bhardwaj N, Brown BD, Greenbaum B, Gumus ZH, Homann D, Horowitz A, Kamphorst AO, Curotto de Lafaille MA, Mehandru S, Merad M, Samstein RM, Sinai Immunology Review P. Immunology of COVID-19: Current State of the Science. Immunity. 2020. Epub 2020/06/09. doi: 10.1016/j.immuni.2020.05.002. PubMed PMID: 32505227; PMCID: PMC7200337 12. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181(5):1036-45 e9. Epub 2020/05/18. doi: 10.1016/j.cell.2020.04.026. PubMed PMID: 32416070; PMCID: PMC7227586. 13. Hadjad J, Yatim N, Barnabei L, et a. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. MedRxiv. 2020;10.1101/2020.04.19.20068015. 14. Bhandage AK, Jin Z, Korol SV, Shen Q, Pei Y, Deng Q, Espes D, Carlsson PO, Kamali-Moghaddam M, Birnir B. GABA Regulates Release of Inflammatory Cytokines From Peripheral Blood Mononuclear Cells and CD4(+) T Cells and Is Immunosuppressive in Type 1 Diabetes. EBioMedicine. 2018;30:283-94. Epub 2018/04/09. doi: 10.1016/j.ebiom.2018.03.019. PubMed PMID: 29627388; PMCID: PMC5952354. 15. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty S, Wang H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Muenker MC, Fournier JB, Campbell M, Odio CD, Casanovas-Massana A, Yale IT, Herbst R, Shaw AC, Medzhitov R, Schulz WL, Grubaugh ND, Dela Cruz C, Farhadian S, Ko AI, Omer SB, Iwasaki A. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature.2020;584(7821):463-9. Epub 2020/07/28. doi: 10.1038/s41586-020-2588-y. PubMed PMID: 32717743. 16. De Albuquerque N, Baig E, Ma X, Zhang J, He W, Rowe A, Habal M, Liu M, Shalev I, Downey GP, Gorczynski R, Butany J, Leibowitz J, Weiss SR, McGilvray ID, Phillips MJ, Fish EN, Levy GA. Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. J Virol. 2006;80(21):10382-94. Epub 2006/10/17. doi: 10.1128/JVI.00747-06. PubMed PMID: 17041219; PMCID: PMC1641767. 17. Khanolkar A, Hartwig SM, Haag BA, Meyerholz DK, Epping LL, Haring JS, Varga SM, Harty JT. Protective and pathologic roles of the immune response to mouse hepatitis virus type 1: implications for severe acute respiratory syndrome. J Virol. 2009;83(18):9258-72. Epub 2009/07/03. doi: 10.1128/JVI.00355-09. PubMed PMID: 19570864; PMCID: PMC2738266. 18. Khanolkar A, Hartwig SM, Haag BA, Meyerholz DK, Harty JT, Varga SM. Toll- like receptor 4 deficiency increases disease and mortality after mouse hepatitis virus type 1 infection of susceptible C3H mice. J Virol. 2009;83(17):8946-56. Epub 2009/06/26. doi: 10.1128/JVI.01857-08. PubMed PMID: 19553337; PMCID: PMC2738158. 19. Khanolkar A, Fulton RB, Epping LL, Pham NL, Tifrea D, Varga SM, Harty JT. T cell epitope specificity and pathogenesis of mouse hepatitis virus-1-induced disease in susceptible and resistant hosts. J Immunol. 2010;185(2):1132-41. Epub 2010/06/18. doi: 10.4049/jimmunol.0902749. PubMed PMID: 20554960; PMCID: PMC2897948. 20. Jin N, Kolliputi N, Gou D, Weng T, Liu L. A novel function of ionotropic gamma- aminobutyric acid receptors involving alveolar fluid homeostasis. J Biol Chem. 2006;281(47):36012-20. Epub 2006/09/28. doi: 10.1074/jbc.M606895200. PubMed PMID: 17003036. 21. Xiang YY, Chen X, Li J, Wang S, Faclier G, Macdonald JF, Hogg JC, Orser BA, Lu WY. Isoflurane regulates atypical type-A gamma-aminobutyric acid receptors in alveolar type II epithelial cells. Anesthesiology. 2013;118(5):1065-75. Epub 2013/03/15. doi: 10.1097/ALN.0b013e31828e180e. PubMed PMID: 23485993. 22. Bai D, Fang L, Xia S, Ke W, Wang J, Wu X, Fang P, Xiao S. Porcine deltacoronavirus (PDCoV) modulates calcium influx to favor viral replication. Virology. 2020;539:38-48. Epub 2019/11/02. doi: 10.1016/j.virol.2019.10.011. PubMed PMID: 31670218; PMCID: PMC7112098. 23. Kraeft SK, Chen DS, Li HP, Chen LB, Lai MM. Mouse hepatitis virus infection induces an early, transient calcium influx in mouse astrocytoma cells. Exp Cell Res. 1997;237(1):55-62. Epub 1998/01/07. doi: 10.1006/excr.1997.3768. PubMed PMID: 9417866; PMCID: PMC7133765. 24. Huang T, Zhang Y, Wang C, Gao J. Propofol reduces acute lung injury by up- regulating gamma-aminobutyric acid type a receptors. Exp Mol Pathol. 2019;110:104295. Epub 2019/08/17. doi: 10.1016/j.yexmp.2019.104295. PubMed PMID: 31419406. 25. Kaynar G, Yurdakan G, Comert F, Yilmaz-Sipahi E. Effects of peripheral benzodiazepine receptor ligand Ro5-4864 in four animal models of acute lung injury. J Surg Res. 2013;182(2):277-84. Epub 2012/11/07. doi: 10.1016/j.jss.2012.10.023. PubMed PMID: 23127280. 26. Fortis S, Spieth PM, Lu WY, Parotto M, Haitsma JJ, Slutsky AS, Zhong N, Mazer CD, Zhang H. Effects of anesthetic regimes on inflammatory responses in a rat model of acute lung injury. Intensive Care Med. 2012;38(9):1548-55. Epub 2012/06/20. doi: 10.1007/s00134-012-2610-4. PubMed PMID: 22711173; PMCID: PMC4896809. 27. Chintagari NR, Liu L. GABA receptor ameliorates ventilator-induced lung injury in rats by improving alveolar fluid clearance. Crit Care. 2012;16(2):R55. Epub 2012/04/07. doi: 10.1186/cc11298. PubMed PMID: 22480160; PMCID: PMC3681384. 28. Jin S, Merchant ML, Ritzenthaler JD, McLeish KR, Lederer ED, Torres- Gonzalez E, Fraig M, Barati MT, Lentsch AB, Roman J, Klein JB, Rane MJ. Baclofen, a GABABR agonist, ameliorates immune-complex mediated acute lung injury by modulating pro-inflammatory mediators. PLoS One. 2015;10(4):e0121637. doi: 10.1371/journal.pone.0121637. PubMed PMID: 25848767; PMCID: PMC4388838. 29. Otomo E, Araki G, Mori A, Kurihara M. Clinical evaluation of GABA in the treatment of cerebrovascular disorders. Multi-center double-blind study in comparison with pyrithioxine and placebo. Arzneimittelforschung. 1981;31(9):1511-23. PubMed PMID: 7030354. 30. Loeb C, Benassi E, Bo GP, Cocito L, Maffini M, Scotto P. Preliminary evaluation of the effect of GABA and phosphatidylserine in epileptic patients. Epilepsy Res. 1987;1(3):209-12. PubMed PMID: 3143549. 31. Tower DB, Roberts E, editors. Inhibition in the Nervous System and GABA. New York: Pergamon Press; 1960. 32. Li J, Zhang Z, Liu X, Wang Y, Mao F, Mao J, Lu X, Jiang D, Wan Y, Lv JY, Cao G, Zhang J, Zhao N, Atkinson M, Greiner DL, Prud'homme GJ, Jiao Z, Li Y, Wang Q. Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics. Front Pharmacol. 2015;6:260. doi: 10.3389/fphar.2015.00260. PubMed PMID: 26617516; PMCID: PMC4639630.